Lin Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019
April 28, 2020 at 08:04 pm EDT
Share
Lin BioScience, Inc. announced earnings results for the full year ended December 31, 2019. For the full year, the company announced operating loss was TWD 238.221 million compared to TWD 155.604 million a year ago. Net loss was TWD 235.256 million compared to TWD 138.516 million a year ago. Basic loss per share was TWD 3.95 compared to TWD 2.33 a year ago.
LIN BIOSCIENCE, INC. is a Taiwan-based company mainly engaged in the development of new pharmaceutical drugs. The Company is in the research and development and clinical trials stage. It has four major drugs in development, including LBS-008, LBS-007, LBS-009 and LBS-002, as well as two technical platforms of RBP4 and CDC7. LBS-008 is developed for dry macular degeneration which belongs to the best-selling drugs, and stel lesions which belongs to orphan drugs. LBS-007 is used in acute leukemia which belongs to orphan drugs, and solid tumors which belongs to the best-selling drugs. LBS-009 is used in non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) and type 2 diabetes. LBS-002 is developed for primary brain cancer and metastatic brain cancer. RBP4 platform is used for metabolic diseases, and CDC7 platform is used for all cancers.